Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients - The Lancet

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients - The Lancet: In December, 2020, the Israeli Government approved the BNT162b2 COVID-19 vaccine and initiated a national immunisation campaign prioritising health-care workers (HCWs), as in other countries.1 This campaign coincided with a third wave of COVID-19, peaking at 10 116 daily new cases by mid-January, 2021. The Sheba Medical Centre, Israel's largest hospital with 9647 HCWs, began staff vaccination on Dec 19, 2020. All HCWs, excluding those with previous SARS-CoV-2 infection, were eligible for vaccination.